10/29
08:05 am
nkgn
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
High
Report
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
10/15
08:05 am
nkgn
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
High
Report
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
10/8
08:05 am
nkgn
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Medium
Report
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
9/12
08:05 am
nkgn
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
Medium
Report
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
9/3
08:05 am
nkgn
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
8/22
04:40 pm
nkgn
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
Medium
Report
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report